2024-09-02 - Analysis Report
## JNJ Stock Analysis Report

This report provides an analysis of Johnson & Johnson (JNJ), a multinational pharmaceutical, medical devices, and consumer packaged goods company, based on the provided data.

**1. Performance Comparison:**

* **JNJ Cumulative Return:** 19.88%
* **S&P 500 (VOO) Cumulative Return:** 89.66%
* **Performance Gap:** -69.78%
* **Relative Performance:** 12.84% (This indicates JNJ's performance is currently at the 12.84th percentile of its historical performance relative to the S&P 500).

**2. Recent Price Movements:**

* **Closing Price:** 165.86
* **5-Day Moving Average:** 164.31
* **20-Day Moving Average:** 161.22
* **60-Day Moving Average:** 154.17

**3. Technical Indicators:**

* **RSI:** 74.35 (The RSI indicates the stock is currently in overbought territory, suggesting potential for a short-term correction.)
* **PPO:** 0.09 (A positive PPO indicates upward momentum.)
* **Delta_Previous_Relative_Divergence:** -9.44 (This indicates a recent short-term decline in relative performance compared to the S&P 500.)
* **Expected Return:** 11.93% (This is the estimated maximum potential return over the next 5 years based on current investment amount.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

The latest earnings report for Q2 2024 showed EPS of $1.95, exceeding analyst expectations. Revenue for the quarter came in at $22.45 billion, also beating estimates. This suggests strong performance and continued growth in JNJ's core businesses.

**5. Overall Analysis:**

While JNJ has demonstrated strong recent earnings performance, its overall performance lags significantly behind the S&P 500.  Technical indicators suggest the stock may be overbought, hinting at potential short-term weakness. Nevertheless, the company's solid earnings track record and projected future growth potential remain positive factors.

**6. Conclusion:**

JNJ's current valuation appears to be inflated considering its recent underperformance against the market. The stock is currently in overbought territory, which may lead to short-term corrections. However, the company's strong earnings and long-term growth potential should not be overlooked. Investors seeking exposure to the pharmaceutical and healthcare sectors may consider adding JNJ to their portfolios, but should be cautious of potential short-term volatility. 
